Loading interface...

Telmisat-H (12.5/80 mg) Tablet

Manufactured byBiocon Ltd.
ContainsHydrochlorothiazide (12.5 mg) + Telmisartan (80 mg)
Description
Telmisat-H (12.5/80 mg) Tablet is a medicine with the combination of hydrochlorothiazide and telmisartan. This medicine lowers your blood pressure by relaxing the blood vessels and removing excess water and sodium from your body. Lowering your blood pressure reduces your chances of having a heart attack or stroke in the future. Telmisat-H (12.5/80 mg) Tablet shows common side effects like tiredness, nausea, diarrhoea, shortness of breath, and heartbeat changes. Consult your doctor if the side effects persist for a long time. This medicine may cause dizziness, so get up slowly when you rise from a sitting or lying down position. Telmisat-H (12.5/80 mg) Tablet is not recommended during pregnancy and breastfeeding. If you have any medical conditions of the heart, liver and kidney, or diabetes, consult your doctor before taking it. Drinking alcohol can further decrease your blood pressure and leading to severe side effects. Telmisat-H (12.5/80 mg) Tablet can be taken with or without food. It contains a diuretic (water pill) which will make you urinate more, so avoid taking it within four hours before going to bed. Do not stop taking this medicine before consulting your doctor. Your blood pressure may seem to be in control, but stopping this medicine abruptly may lead to a high risk of heart attack and stroke.

Side effects

Major & minor side effects for Telmisat-H (12.5/80 mg) Tablet

  • Increased urination
  • Itching or rash
  • Stomach pain
  • Dry mouth
  • Joint pain, stiffness, and swelling
  • Cramping
  • Chest pain
  • Changes in vision
  • Dizziness
  • Increased heartbeat
  • Difficult or painful urination
  • Headache
  • Diarrhoea
  • Back pain
  • Weakness
  • Muscle pain
  • Fever

Uses of Telmisat-H (12.5/80 mg) Tablet

What is it prescribed for?

  • Hypertension
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of Telmisat-H (12.5/80 mg) Tablet can be observed within 2 hours of intake.
  • How long do the effects of this medicine last?
    The effect of Telmisat-H (12.5/80 mg) Tablet lasts for an average duration of 24 hours.
  • Is it safe to consume alcohol while taking this medicine?
    Telmisat-H (12.5/80 mg) Tablet and alcohol may have an additive effect in decreasing your blood pressure. Headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate are all possible symptoms that you may experience if you consume alcohol while on treatment with this medicine. Hence, it is advised to avoid alcohol consumption when taking this medicine.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported for Telmisat-H (12.5/80 mg) Tablet.
  • Can this medicine be taken during pregnancy?
    Telmisat-H (12.5/80 mg) Tablet is not recommended for use in pregnancy. There have been some human studies that have revealed harmful effects on the growing foetus. Inform your doctor of your pregnancy while taking this medicine.
  • Can this medicine be taken while breast-feeding?
    Telmisat-H (12.5/80 mg) Tablet is unsafe to be taken during breastfeeding. According to limited human research, the medication may enter into breastmilk and harm your baby. Consult your doctor if you are breastfeeding while on this medication.

Allergy

Telmisat-H (12.5/80 mg) Tablet is not recommended for use if you have a known allergy to the contents of this medicine. Allergic reactions such as hives (painful eruptions that itch and sting), difficulty breathing, swelling of your face, lips, tongue, or throat should be reported to your doctor.

Anuria

Anuria is a condition where the kidney is unable to produce urine. Hydrochlorothiazide is present in Telmisat-H (12.5/80 mg) Tablet which acts by removing excess water and sodium from your body. If your kidney is already damaged, using this medicine will worsen the condition. Thus, this medicine is not recommended if you have anuria.

Cholestasis and biliary obstructive disorders

If you have severe liver conditions, such as cholestasis or biliary obstruction then Telmisat-H (12.5/80 mg) Tablet should not be taken. Cholestasis is a condition in which the flow of bile (fluid secreted by the liver for digestion) is reduced. Biliary obstruction is blockage or obstruction of bile flow from the liver and gallbladder. Telmisat-H (12.5/80 mg) Tablet contains telmisartan which is mainly excreted in the bile. In such liver conditions, telmisartan will get accumulated in the liver and cause severe damages.

Angioedema

Angioedema is an allergic reaction to any food, medicine or pollen in which there is a painless swelling under the skin. Symptoms of angioedema are swelling of the face, extremities, eyes, lips, or tongue, as well as trouble swallowing or breathing. Telmisat-H (12.5/80 mg) Tablet is not recommended if you have a history of angioedema as a result of using hydrochlorothiazide, or for those who have genetic angioedema.
Warnings for special population

Pregnancy

Telmisat-H (12.5/80 mg) Tablet is not recommended for use in pregnancy. There have been some human studies that have revealed harmful effects on the growing foetus. Inform your doctor of your pregnancy while taking this medicine.

Breast-feeding

Telmisat-H (12.5/80 mg) Tablet is unsafe to be taken during breastfeeding. According to limited human research, the medication may enter into breastmilk and harm your baby. Consult your doctor if you are breastfeeding while on this medication.
General warnings

Volume and electrolyte depletion

Telmisat-H (12.5/80 mg) Tablet may alter your blood volume and electrolyte levels. This may cause dizziness, dry mouth, and acid-base imbalance (an imbalance between the levels of carbon dioxide and bicarbonates in the blood). This risk is especially higher if you have kidney or liver problems. Consult your doctor if you experience any of these symptoms.

Use in athletes

Telmisat-H (12.5/80 mg) Tablet is not recommended to be used by athletes as per the World Anti-Doping Agency (WADA).

Hyperkalemia

Hyperkalemia is an increase of potassium levels in your blood. Telmisat-H (12.5/80 mg) Tablet may increase the potassium levels leading to serious side effects such as heart rhythm irregularities (improper beating of the heart). It is advised that you avoid potassium-rich foods (potatoes, bananas) and other medicines that may increase potassium levels (ACE inhibitors and potassium supplements) during treatment with this medicine.

Liver diseases

Telmisat-H (12.5/80 mg) Tablet should be used with extreme caution if you have liver diseases. Telmisartan present in this medicine is largely excreted in bile (fluid secreted by the liver for digestion). Using this medicine while you have pre-existing liver problems can worsen your condition. This can increase the risk of serious side effects.

Use in children

Telmisat-H (12.5/80 mg) Tablet is not recommended for use in children below 18 years of age because the safety and efficacy data is not available.

Kidney diseases

Telmisat-H (12.5/80 mg) Tablet has hydrochlorothiazide as a content, which increases the frequency of urination.If you have pre-existing kidney problems, this medicine can further worsen your condition.

Missed Dose

If you forget to take a dose of Telmisat-H (12.5/80 mg) Tablet, take it as soon as you remember. If the next dose timing is near, skip the missed dose. Take your next dose at your usual time. Do not double up your dose to compensate for a missed dose.

Overdose

In case of overdose, you may experience symptoms like lethargy, drowsiness, nausea and vomiting. Seek immediate medical attention if you have taken an overdose of Telmisat-H (12.5/80 mg) Tablet.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Telmisat-H (12.5/80 mg) Tablet and alcohol may have an additive effect in decreasing your blood pressure. Headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate are all possible symptoms that you may experience if you consume alcohol while on treatment with this medicine. Hence, it is advised to avoid alcohol consumption when taking this medicine.
Interaction with Medicine

Aliskiren

Pregabalin

Aspirin

Disease interactions

Diabetes

Diabetes is a condition in which your blood sugar levels are abnormally high. Telmisat-H (12.5/80 mg) Tablet increases the risk of altered blood glucose levels. People having diabetes should use this medicine with caution. Your doctor will advise you to monitor your blood glucose levels regularly while you are taking this medicine.

Hyperuricemia

Hyperuricemia is an increased level of uric acid in the blood. Using Telmisat-H (12.5/80 mg) Tablet while you have a pre-existing kidney problem like chronic kidney failure will further worsen your condition. Your blood uric acid levels will be closely monitored by your doctor while you are on treatment with this medicine.

Hypotension

Hypotension is a decrease in your blood pressure. Using Telmisat-H (12.5/80 mg) Tablet will further reduce your blood pressure which can be fatal, especially if you have low levels of sodium in your body or if you have low fluid volumes due to excessive vomiting, diarrhoea, burns, kidney failure, etc.
Food interactions
It is advised to avoid potassium-containing foods (potatoes, bananas and tomatoes) and supplements while taking Telmisat-H (12.5/80 mg) Tablet due to the increased risk of weakness, confusion, irregular heartbeat, etc. Report such symptoms to the doctor immediately. Your dietitian/doctor may suggest appropriate changes in your diet based on your clinical condition.
Lab interactions
Information not available.
Take Telmisat-H (12.5/80 mg) Tablet with or without food. Do not take in larger amounts than prescribed. Telmisat-H (12.5/80 mg) Tablet may cause dehydration. Drink plenty of fluids and inform your doctor if you develop extreme thirst, dry mouth or muscle weakness. It may cause dizziness. Get up slowly when you rise from a sitting or lying position. Consult your doctor if you experience any undesirable effects. Do not stop taking the medicine without consulting your doctor as it may cause withdrawal symptoms. Do not chew, crush or break the tablet. Take the tablet immediately after peeling it from the strip.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
Hydrochlorothiazide is a diuretic (water pill) that removes excess water and sodium from your body. It also relaxes blood vessels and promotes the smooth flow of blood. Telmisartan works by blocking the action of angiotensin (a hormone that narrows blood vessels), causing blood vessels to relax. This improves blood flow and helps the heart to pump more efficiently. Thus Telmisat-H (12.5/80 mg) Tablet helps to lower the blood pressure.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Angiotensin receptor blockers, Thiazide diuretics, Angiotensin II inhibitors with thiazides, Antihypertensive combinations, Angiotensin receptor blockers and thiazide diuretics

Schedule

Schedule H

Dailymed.nlm.nih.gov. 2021. DailyMed - TELMISARTAN AND HYDROCHLOROTHIAZIDE 40 MG/12.5 MG- telmisartan and hydrochlorothiazide tabletTELMISARTAN AND HYDROCHLOROTHIAZIDE 80 MG/12.5 MG- telmisartan and hydrochlorothiazide tabletTELMISARTAN AND HYDROCHLOROTHIAZIDE 80 MG/25 MG- telmisartan and hydrochlorothiazide tablet. [online] Available at: < [Accessed 16 June 2021].

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b476740-e3f0-4f68-b07c-cd9eb2fa27ca>

Medicines.org.uk. 2021. Telmisartan/Hydrochlorothiazide 80 mg/12.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 16 June 2021].

https://www.medicines.org.uk/emc/product/8604/smpc#gref>

Accessdata.fda.gov. 2021. [online] Available at: < [Accessed 30 July 2021].

https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf>

Accessdata.fda.gov. 2021. [online] Available at: < [Accessed 30 July 2021].

https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020850s032lbl.pdf>
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 3 Sep 2021

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.